The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists
West, Catharine ML
AffiliationDepartment of Radiation Oncology, Medical College of Wisconsin, 9200 West Wisconsin Ave, Milwaukee, USA
MetadataShow full item record
AbstractPURPOSE AND METHODS: The advent of affordable and rapid next-generation DNA sequencing technology, along with the US Supreme Court ruling invalidating gene patents, has led to a deluge of germline and tumor genetic variant tests that are being rapidly incorporated into clinical cancer decision making. A major concern for clinicians is whether the presence of germline mutations may increase the risk of radiation toxicity or secondary malignancies. Since minimal clinical data exist to inform decisions at this time, the American Society for Radiation Oncology (ASTRO) convened a group of radiation science experts and clinicians to summarize potential issues, review relevant data, and provide guidance for adult patients and their care teams regarding the impact, if any, that genetic testing should have on radiation therapy recommendations. RESULTS AND CONCLUSIONS: During the ASTRO Workshop, several main points emerged, which are discussed in this manuscript: 1) Variants of uncertain significance should be considered non-deleterious until functional genomic data emerges to demonstrate otherwise; 2) Possession of germline alterations in a single copy of a gene critical for radiation damage responses does not necessarily equate to increased risk of radiation-induced toxicity; 3) Deleterious ATM mutations may modestly increase second cancer risk after radiotherapy, thus follow-up for these patients after indicated radiotherapy should include second cancer screening; 4) Conveying to patients the difference between relative and absolute risk is critical to decision making; and 5) More work is needed to assess the impact of tumor somatic alterations on the probability of response to radiotherapy and the potential for individualization of radiation doses. Data on radiosensitivity related to specific genetic mutations is also briefly discussed.
CitationBergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, et al. The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists. Int J Radiat Oncol Biol Phys. 2019 Aug 2.
JournalInternational Journal of Radiation Oncology Biology Physics
- Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
- Authors: Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I, CoF-AT., GENESIS., kConFab., Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F
- Issue date: 2018 Apr 17
- ATM Mutations in Cancer: Therapeutic Implications.
- Authors: Choi M, Kipps T, Kurzrock R
- Issue date: 2016 Aug
- Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients.
- Authors: Chistiakov DA, Voronova NV, Chistiakov PA
- Issue date: 2008
- Germline genetic variants in men with prostate cancer and one or more additional cancers.
- Authors: Pilié PG, Johnson AM, Hanson KL, Dayno ME, Kapron AL, Stoffel EM, Cooney KA
- Issue date: 2017 Oct 15
- Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review.
- Authors: Bernier J, Poortmans P
- Issue date: 2015 Apr